Eli Lilly (LLY) stock soars after FDA approves Foundayo - can this weight-loss pill drive massive growth as investors bet big on obesity drug boom

Eli Lilly (LLY) stock today: Shares of Eli Lilly (LLY) moved higher on Wednesday, jumping more than 5% after the US FDA approved its new oral weight-loss drug, Foundayo, giving the company a stronger foothold in the fast-growing obesity treatment market.

Eli Lilly Stock Today Jumps After FDA Nod for Foundayo - LLY Stock Outperforms Healthcare Sector and S&P 500

The once-daily pill, known scientifically as orforglipron, marks Lilly’s second FDA-approved obesity therapy. Investors reacted positively to the development, pushing the stock higher and helping it outperform the broader healthcare sector, which was also in the green alongside gains in the S&P 500.

Clinical data appears to be a key driver behind the optimism. In the ATTAIN-1 trial, adults taking the highest dose of Foundayo lost an average of 27 pounds, or 12.4% of their body weight, as per a Benzinga report. Over longer trials, weight reduction ranged between 12% and 15%, with results plateauing for many patients over time.

Foundayo Pricing, Access, and Medicare Availability Explained

Lilly is also positioning the drug aggressively on pricing and access. Foundayo will be available through its LillyDirect platform at $25 per month for commercially insured patients and $149 for self-pay users. Medicare Part D patients could access it for $50 per month starting July 2026. The company noted the drug should not be used alongside other GLP-1 receptor agonists.

FDA Nod for Foundayo Strengthens Eli Lilly’s Obesity Drug Portfolio

From a market perspective, the approval is significant. It strengthens Lilly’s standing in the obesity space, particularly as oral treatments are expected to capture a meaningful share of the market in the coming years. The pill’s convenience, taken without timing restrictions, adds to its appeal compared to some competing treatments.

Technical Analysis: What RSI and MACD Say About Eli Lilly Shares

Technically, the stock is showing mixed signals. Shares are trading slightly above their 20-day moving average but remain below the 100-day level. Momentum indicators are also divided, with a neutral RSI and a bearish MACD suggesting some near-term pressure despite the positive news.

Analyst Ratings and Price Targets for Eli Lilly Stock

Still, the broader trend remains strong. The stock has gained over 20% in the past year and continues to trade closer to its 52-week highs. Analysts maintain a Buy rating overall, with an average price target of $1,177.40, even as some firms have adjusted their outlooks, as per the Benzinga report.

Eli Lilly Earnings Preview: Can Foundayo Drive Future Growth

With its next earnings update scheduled for April 30, 2026, the spotlight now shifts to whether Foundayo’s launch can translate into sustained revenue growth and justify the company’s premium valuation.

FAQs

How effective is Foundayo for weight loss?

In trials, patients lost about 12%–15% of their body weight on average.

Why is this approval important for Eli Lilly?

It strengthens the company’s position in the growing obesity treatment market.